WHO estimates 660,000 cases of mother-to-child transmission of syphilis (congenital syphilis) occurred in 2016, resulting in 350,000 adverse birth outcomes inclusive of over 200,000 stillbirths and neonatal deaths. By comparison, UNAIDS estimates approximately 180,000 new cases of HIV occurred in 2016 among children ages 0-14 years. Although over 90% of countries include screening of pregnant women for syphilis in national antenatal care guidance, efforts to ensure high screening coverage have seen limited improvement, resulting in static estimates of congenital syphilis in the setting of stable or increasing syphilis prevalence among general and high-risk populations of adults. In 2016, WHO estimated 66% coverage of syphilis screening among pregnant women with an estimated global syphilis prevalence in this group of 0.69% (0.70% in 2012).
In 2014, WHO launched the initiative “Elimination of Mother-to-Child Transmission of HIV and syphilis” (EMTCT). While 14 countries have been validated by WHO for this achievement, high burden countries in several regions are challenged to achieve the WHO EMTCT criteria of 95% coverage of antenatal care, syphilis testing and treatment of infected pregnant women with benzathine penicillin. Limited national prioritization and stakeholder engagement have resulted in lower coverage of syphilis screening as compared to HIV screening in pregnant women. Recent global shortages of benzathine penicillin have challenged treatment coverage as this medication is currently the only WHO-recommended treatment for pregnant women with syphilis.
Newer technologies including rapid syphilis tests and rapid dual HIV/syphilis tests have offered the opportunity for same-visit testing and treatment of syphilis. The rapid dual HIV/syphilis test offers numerous advantages to separate tests and can be purchased at a similar price to that of a single HIV test. Implementation of the rapid dual HIV/syphilis tests can result in the immediate equalization of syphilis screening coverage to that of HIV among pregnant women. Studies to evaluate alternative treatment regimens for syphilis that could be appropriate for use in pregnant women are underway.